Dr Warner discusses the FDA approval of afami-cel for patients with advanced synovial sarcoma and key findings from the pivotal SPEARHEAD-1 trial.
Allison Betof Warner, MD, PhD
Advertisement
Articles by Allison Betof Warner, MD, PhD
Allison Betof Warner, MD, PhD, discusses the excitement surrounding the findings from the COMBI-i trial that was presented at the 2019 ASCO Annual Meeting. This trial investigated the combination of PD-1 inhibitor spartalizumab with dabrafenib plus trametinib in patients with advanced BRAF V6000mutant melanoma.
Advertisement
Latest Updated Articles
Dr. Warner Discusses Findings from COMBI-i Trial in MelanomaNovember 21st 2019
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
4
Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL
5